Jamjoom Pharma revises up 2023 guidance

10/08/2023 Argaam Special
Logo ofJamjoom Pharma

Logo of Jamjoom Pharma

Jamjoom Pharmaceuticals Factory Co. (Jamjoom Pharma) updated its outlook and guidance for 2023.

 

The pharmaceutical producer revised up its previous guidance for revenues and earnings before interest, taxes, depreciation, and amortization (EBITDA) margins, following the strong growth reported in the first half of 2023. 

 

Period

Actual – H1 2023

Previous Guidance

Updated Guidance

Revenue Growth

+24%

15-17%

17-19%

EBITDA Margin

33.2%

30%

31%

CAPEX

3.2%

--

4-6%
 
The company attributed the 24% rise in revenue to better demand and the price hike applied to some key products in late Q1 2023. Jamjoom Pharma’s manufacturing capacity was ramped up by the end of Q2 2023.

Comments {{getCommentCount()}}

Be the first to comment

{{comment.FollowersCount}}
{{comment.CommenterComments}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}} حساب موثّق

{{comment.ElapsedTime}}
{{comment.Replies.length}}
تعديل
loader Train
Report
loader Train
Sorry: the validity period has ended to comment on this news
Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.